Yesterday drugmaker Medarex
No financial details of the deal were disclosed, except that Medarex and Organon will share in any revenue that comes from drugs that make it to market through the deal. While this probably means that the deal is not doing anything directly positive for Medarex's balance sheet, these sorts of collaboration agreements will help Medarex speed up the pace of running the large number of compounds through its drug pipeline.
Some development-stage biotechs like Medarex and Rule Breakers pick Exelixis
We're beyond the go-go '90s where companies with sexy technologies like Millennium Pharmaceuticals
Millennium Pharmaceuticals and Exelixis are Motley Fool Rule Breakers recommendations. You can check out all our selections as well as get access to our message boards and exclusive content with a 30-day free trial to the newsletter.
Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has a disclosure policy.